Cisplatin treatment of testicular cancer patients introduces long-term changes in the epigenome

BACKGROUND: Cisplatin-based chemotherapy (CBCT) is part of standard treatment of several cancers. In testicular cancer (TC) survivors, an increased risk of developing metabolic syndrome (MetS) is observed. In this epigenome-wide association study, we investigated if CBCT relates to epigenetic change...

Descripción completa

Detalles Bibliográficos
Autores principales: Bucher-Johannessen, Cecilie, Page, Christian M., Haugen, Trine B., Wojewodzic, Marcin W., Fosså, Sophie D., Grotmol, Tom, Haugnes, Hege S., Rounge, Trine B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892132/
https://www.ncbi.nlm.nih.gov/pubmed/31796056
http://dx.doi.org/10.1186/s13148-019-0764-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892132/
https://www.ncbi.nlm.nih.gov/pubmed/31796056
http://dx.doi.org/10.1186/s13148-019-0764-4

Ejemplares similares